Ufovax advances self-assembling nanoparticle COVID-19 vaccine
Vaccine biotechnology company Ufovax announced it will begin phase I clinical trials of its one-component, self-assembling protein nanoparticle (1c-SApNP) SARS-CoV-2 vaccine.
Axon Neuroscience to research COVID-19 vaccine
Clinical-stage biotechnology company Axon Neuroscience plans to start clinical trials of an independently developed, crowdfunded vaccine against COVID-19 called ACvac1.
DIY vaccines are a landmine of public health concerns
A new Science article describes the legal and ethical implications of do-it-yourself (DIY) COVID-19 vaccines.
Elicio, Moffitt to study combination CAR-T therapy
Elicio Therapeutics and the Moffitt Cancer Center have established a collaboration to study Elicio's amphiphile immunotherapies with CD19 chimeric antigen receptor-T (CAR-T) cells.
ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks have announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Lykan opens manufacturing facility for cell therapies
Lykan Bioscience has opened a new, 64,000-sq-ft "smart" manufacturing facility in Hopkinton, MA.
Moderna, Vertex collaborate on gene editing therapies for cystic fibrosis
Moderna and Vertex Pharmaceuticals have entered a three-year research collaboration for the discovery and development of lipid nanoparticles and messenger RNAs for the delivery of gene editing therapies for the treatment of cystic fibrosis.
Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.
Agilent offers new flow cytometers
Agilent Technologies has launched a new product offering, the Agilent NovoCyte Penteon, a flow cytometer with five lasers and up to 30 fluorescence channels.
AVM Bio to begin trial of COVID-19 immunotherapy
AVM Biotechnology received authorization for an investigational new drug application from the U.S. Food and Drug Administration to evaluate its proprietary drug, AVM0703, in the treatment of acute respiratory distress syndrome mediated by COVID-19 or influenza patients.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter